Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 25 of 226 for:    warfarin AND International

CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02139072
Recruitment Status : Completed
First Posted : May 15, 2014
Last Update Posted : October 4, 2016
Sponsor:
Collaborator:
Hoffmann-La Roche
Information provided by (Responsible Party):
University of Florida

Brief Summary:
The purpose of this study is to see if the CoaguChek XS is accurate in measuring International Normalized Ratio (INR) in patients with Antiphospholipid Antibody Syndrome (APL) receiving warfarin therapy.

Condition or disease Intervention/treatment
Antiphospholipid Antibody Syndrome Device: CoaguChek XS Procedure: Standard Lab Draw

Detailed Description:
Antiphospholipid Antibody Syndrome (APL) is an autoimmune disease that increases ones risk for blood clots. Therefore, these patients receive anticoagulation therapy with warfarin. Point of care devices such as the CoaguChek XS are often used to monitor International Normalized Ratio (INR) in patients on warfarin. However, the antibodies present in patients with APL may lead to false INR results when using the CoaguChek XS. This study will compare the accuracy of the CoaguChek XS in measuring INR in patients with APL by measuring INR by the CoaguChek XS and a standard lab as a reference point. Patients on warfarin for indications other than APL will be measured by both methods as well to serve as a control group.

Layout table for study information
Study Type : Observational
Actual Enrollment : 60 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Accuracy of CoaguChek XS in Patients With Antiphospholipid Antibody Syndrome
Study Start Date : March 2015
Actual Primary Completion Date : January 2016
Actual Study Completion Date : January 2016

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
CoaguChek XS
INR measured by CoaguChek XS in patients with APL at visit 1 and visit 2, in addition to routine measure by standard lab draw
Device: CoaguChek XS
CoaguChek XS will be used to measure INR in patients with APL

Procedure: Standard Lab Draw
Patients on warfarin for any indication other than APL will measure INR by venous lab draw

Standard Lab Draw
INR measured by standard lab draw at visit 1 and visit 2 for non-APL patients, in addition to routine measurement by CoaguChek XS
Device: CoaguChek XS
CoaguChek XS will be used to measure INR in patients with APL

Procedure: Standard Lab Draw
Patients on warfarin for any indication other than APL will measure INR by venous lab draw




Primary Outcome Measures :
  1. International Normalized Ratio (INR) [ Time Frame: Day 1 and Day 60 ]
    Compare INR obtained by CoaguChek XS to INR obtained from venous lab draw. Difference of +/- 0.5 considered significant



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients presenting to UF/Shands Hematology Anticoagulation Clinic for a routine office visit with pharmacy.
Criteria

Inclusion Criteria:

  • 18-65 years of age
  • anticoagulated with warfarin for at least 1 month
  • Diagnosis of antiphospholipid antibody syndrome for intervention arm

Exclusion Criteria:

  • any type of mental disability that would hinder their ability to give informed consent
  • any terminal illness or any other condition that could interfere with study completion, that person will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02139072


Locations
Layout table for location information
United States, Florida
UF and Shands Health
Gainesville, Florida, United States, 32610
Sponsors and Collaborators
University of Florida
Hoffmann-La Roche
Investigators
Layout table for investigator information
Principal Investigator: James Taylor, PharmD University of Florida

Layout table for additonal information
Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT02139072     History of Changes
Other Study ID Numbers: IRB201400096
First Posted: May 15, 2014    Key Record Dates
Last Update Posted: October 4, 2016
Last Verified: January 2016
Keywords provided by University of Florida:
Anticoagulation
International normalized ratio
Warfarin
Additional relevant MeSH terms:
Layout table for MeSH terms
Antiphospholipid Syndrome
Syndrome
Disease
Pathologic Processes
Autoimmune Diseases
Immune System Diseases
Antibodies
Antibodies, Antiphospholipid
Immunologic Factors
Physiological Effects of Drugs